Presentation is loading. Please wait.

Presentation is loading. Please wait.

Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.

Published byOlof Sandberg Modified over 5 years ago

Similar presentations

Presentation on theme: "Discovery of Gö6976-related potent reversible EGFR T790M inhibitors."— Presentation transcript:

1 Discovery of Gö6976-related potent reversible EGFR T790M inhibitors.
Discovery of Gö6976-related potent reversible EGFR T790M inhibitors. A, in vitro inhibition of recombinant EGFR autophosphorylation by Gö6976 or erlotinib. Recombinant EGFR wild-type, T790M, or L858R/T790M was phosphorylated by addition of ATP for 15 minutes in the presence of the indicated concentrations of Gö6976 or erlotinib. Immunoblots show autophosphorylated tyrosine residues in EGFR and total EGFR. B, chemical structures of Gö6976 and the structurally related Cep-701 and PKC412 inhibitors. C, comparison of Cep-701 and PKC412 for their inhibitory activities on EGFR T790M. Each recombinant EGFR protein was subjected to an autophosphorylation assay in the presence of ATP with Cep-701 or PKC412 for 15 minutes. D, viability assay of NCI-H1975 or NCI-H322 cells treated with Gö6976, Cep-701, PKC412 or erlotinib. NCI-H1975 or NCI-H322 cells were treated with various concentrations of the indicated inhibitors for 72 hours. Error bars, mean ± SEM. pTyr, phosphorylated tyrosine. Ho-June Lee et al. Cancer Discovery 2013;3: ©2013 by American Association for Cancer Research

Download ppt "Discovery of Gö6976-related potent reversible EGFR T790M inhibitors."

Similar presentations

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.
Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.

Defining Epidermal Growth Factor Receptor exon 20 mutant sensitivity to tyrosine kinase inhibition Danny Rayes.
Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.

Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.
AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.

AZD9291 inhibits EGFR phosphorylation and downstream signaling in murine models of EGFRT790M-resistant lung cancer. AZD9291 inhibits EGFR phosphorylation.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.

PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.
ARG tyrosine kinase activity is inhibited by STI571

ARG tyrosine kinase activity is inhibited by STI571
Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.

Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.
Volume 65, Issue 1, Pages (January 2017)

Volume 65, Issue 1, Pages (January 2017)
NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.

NF1 silencing confers resistance of PC9 lung adenocarcinoma cells to erlotinib (erl). NF1 silencing confers resistance of PC9 lung adenocarcinoma cells.
Recombinant OPCML protein effect in vitro.

Recombinant OPCML protein effect in vitro.
Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.

Combined inhibition of MAP kinase and KIT signaling destabilizes ETV1 protein and results in enhanced growth suppression of human GIST cells. Combined.
Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer  Hiroyuki.

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer  Hiroyuki.
PDK1 regulates PLK1 in vivo and in vitro.

PDK1 regulates PLK1 in vivo and in vitro.
Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis 

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis 
PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.

PDGFRβ is dispensable for EGFRvIII-driven GBM growth but is required for the optimal growth of EGFR-inhibited tumors. PDGFRβ is dispensable for EGFRvIII-driven.
Volume 1, Issue 5, Pages (June 2002)

Volume 1, Issue 5, Pages (June 2002)
NF1 downregulation activates MAPK pathway signaling.

NF1 downregulation activates MAPK pathway signaling.
A20 inhibits caspase-8 cleavage and TRAIL-induced apoptosis.

A20 inhibits caspase-8 cleavage and TRAIL-induced apoptosis.
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

Similar presentations

Ads by Google